New hope for recurrent brain cancer? atezolizumab trial targets tumor biomarkers
NCT ID NCT06069726
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This phase 2 trial is testing whether giving the immunotherapy drug atezolizumab before surgery can help people with recurrent glioblastoma, a type of aggressive brain cancer. Researchers want to see if the drug works better in patients with certain genetic markers (tumor mutational burden). About 80 adults whose cancer has returned after standard treatment will receive one dose of atezolizumab before their tumor is removed. The study focuses on survival and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University
RECRUITINGDurham, North Carolina, 27705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Saint Luke's Cancer Institute
ACTIVE_NOT_RECRUITINGKansas City, Missouri, 64111, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab
What this could lead to
If successful, this could point toward a more personalized treatment for recurrent glioblastoma, potentially improving survival for certain patients.
What could go wrong
This is a small, early-phase trial with only 80 participants. The drug may not improve survival and could cause serious side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.